[
  {
    "ts": "2026-02-14T04:26:33+00:00",
    "headline": "Merck’s KEYTRUDA Wins New Ovarian Cancer Use As Valuation Gap Persists",
    "summary": "Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. The approvals include a companion diagnostic to help identify patients who are eligible for these PD-1 inhibitor based treatments. Merck also entered a collaboration to develop an intravaginal drug delivery platform focused on women's health therapies. For investors watching NYSE:MRK, these approvals and the new delivery...",
    "url": "https://finance.yahoo.com/news/merck-keytruda-wins-ovarian-cancer-042633653.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c3ee5f80-b04a-3dd5-9e09-9674a4945b42",
      "content": {
        "id": "c3ee5f80-b04a-3dd5-9e09-9674a4945b42",
        "contentType": "STORY",
        "title": "Merck’s KEYTRUDA Wins New Ovarian Cancer Use As Valuation Gap Persists",
        "description": "",
        "summary": "Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. The approvals include a companion diagnostic to help identify patients who are eligible for these PD-1 inhibitor based treatments. Merck also entered a collaboration to develop an intravaginal drug delivery platform focused on women's health therapies. For investors watching NYSE:MRK, these approvals and the new delivery...",
        "pubDate": "2026-02-14T04:26:33Z",
        "displayTime": "2026-02-14T04:26:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-keytruda-wins-ovarian-cancer-042633653.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-keytruda-wins-ovarian-cancer-042633653.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-14T13:35:00+00:00",
    "headline": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
    "summary": "These two stocks have historically zigged when the market has zagged.",
    "url": "https://www.fool.com/investing/2026/02/14/unstoppable-dividend-stocks-buy-if-sell-off/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "03cb7aa4-ec33-3a48-bf0c-45b233cf07ea",
      "content": {
        "id": "03cb7aa4-ec33-3a48-bf0c-45b233cf07ea",
        "contentType": "STORY",
        "title": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
        "description": "",
        "summary": "These two stocks have historically zigged when the market has zagged.",
        "pubDate": "2026-02-14T13:35:00Z",
        "displayTime": "2026-02-14T13:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5781c9e3b2339509043cc5ca81b6e81f",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Person at desk in dark office, looking at charts on screens.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M8pETPR60Mkfb2e9ZZ1Zlw--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5781c9e3b2339509043cc5ca81b6e81f.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qvVcImgP.9uUSbVK7t1HRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5781c9e3b2339509043cc5ca81b6e81f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/14/unstoppable-dividend-stocks-buy-if-sell-off/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-unstoppable-dividend-stocks-buy-133500211.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-14T20:02:21+00:00",
    "headline": "Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit",
    "summary": "Vaxcyte (NASDAQ:PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company’s pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on its 31-valent candidate, VAX-31, and the Phase 3 adult program now underway. Focus on pneumococcal co",
    "url": "https://www.marketbeat.com/instant-alerts/vaxcyte-spotlights-vax-31-phase-3-launch-eyes-adult-bla-by-end-of-next-year-at-biotech-summit-2026-02-14/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "ae1679b1-be0f-3858-8e05-381204a21e0c",
      "content": {
        "id": "ae1679b1-be0f-3858-8e05-381204a21e0c",
        "contentType": "STORY",
        "title": "Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit",
        "description": "",
        "summary": "Vaxcyte (NASDAQ:PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company’s pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on its 31-valent candidate, VAX-31, and the Phase 3 adult program now underway. Focus on pneumococcal co",
        "pubDate": "2026-02-14T20:02:21Z",
        "displayTime": "2026-02-14T20:02:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/3e631096112598d1f5354740b68b30ef",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Vaxcyte logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nn.gctPM3Z__deP8o28._A--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/3e631096112598d1f5354740b68b30ef.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R5pSpYpwRM1O.92prBOV2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/3e631096112598d1f5354740b68b30ef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/vaxcyte-spotlights-vax-31-phase-3-launch-eyes-adult-bla-by-end-of-next-year-at-biotech-summit-2026-02-14/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vaxcyte-spotlights-vax-31-phase-200221951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PCVX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]